Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
Sarah J. Shepherd(University of Pennsylvania), Michael J. Mitchell(California Institute for Regenerative Medicine), David Issadore(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Rakan El‐Mayta(University of Pennsylvania), Neha Srikumar(University of Pennsylvania), Marshall S. Padilla(University of Pennsylvania), Jingyu Wu(University of Pennsylvania), Daeyeon Lee(California University of Pennsylvania), Xuexiang Han(Center for Excellence in Molecular Cell Science), Ajay S. Thatte(University of Pennsylvania), Alvin J. Mukalel(University of Pennsylvania)
Cited by 119
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
|Immunity|2021|713
An ionizable lipid toolbox for RNA delivery
|Nature Communications|2021|581
Nanomaterial Delivery Systems for mRNA Vaccines
|Vaccines|2021|546